Development and Validation of a Multiplex qPCR Short Fragment Cell Free DNA Assay as a potential biomarker for predicting Early Non-Response to therapy in Metastatic Cancer (CADEX-001)
Development and Validation of a Multiplex qPCR Short Fragment Cell Free DNA Assay as a potential biomarker for predicting Early Non-Response to therapy in Metastatic Cancer (CADEX-001)
Trial Category:
Other Solid Tumor
Contact(s)
Location(s)
Nebraska Cancer Specialists, Omaha, NE
